How Are Common Pathogens Managed In Patients With Cystic Fibrosis (CF)?
Question
How are common pathogens managed in patients with Cystic Fibrosis (CF)?
Answer
Let's look at different CF pathogens or bacteria. Pseudomonas are among the most common bacteria found in people with CF. More than 60% of adults with Cystic Fibrosis have cultured Pseudomonas. It is not a question of if they will get Pseudomonas, but rather when will they get Pseudomonas. When Pseudomonas is established in the airways, it is challenging to eliminate, but aggressive treatment can delay long-term infections. With the first acquisition of Pseudomonas, we do an eradication protocol, including oral Ciprofloxacin for two weeks and inhaled Tobramycin for a whole month.
If patients continue to colonize Pseudomonas, they will be on an antibiotic regimen. Including inhaled Tobramycin every other month or dual therapy, including Tobramycin one month and then another anti-pseudomonal drug, most often Casein, the following month. Other CF pathogens include methicillin-resistant staphylococcus aureus (MRSA), a prevalent bacteria found on skin surfaces. We only treat it during exacerbations. Burkholderia cepacia is another CF pathogen. This germs live in damp places and are often difficult to treat once it infects the lungs. Aspergillus is a common mold fungus found indoors or outdoors. It causes a disease called aspergillosis, which usually only develops in people with weakened immunity or lung disease.
Non-tuberculous mycobacteria (NTM) are another group of bacteria that can affect Cystic Fibrosis patients. This group of bacteria lives in soil, swamps, and water sources. NTM can survive many disinfectants and even severe environmental conditions. These have been found in a growing number of CF people, especially those with advanced lung disease. The treatment for NTM is very lengthy, usually, 6 to 12 months with several oral antibiotics, coupled with inhaled antibiotics. Therefore, the CF Foundation guidelines state that all CF patients who can expectorate sputum should have an acid-fast bacilli (ASB) culture sent annually to monitor NTM.
This Ask the Expert is an edited excerpt from Prigi Varghese, MSN, APRN, CPNP-PC.
Prigi Varghese
MSN, APRN, CPNP-PC
Related Courses
Revisiting Adverse Childhood Experiences: Is This the Key to Managing COPD
A landmark study conducted by Kaiser-Permanente established a solid relationship between adverse childhood experiences (ACEs) and the development of Chronic Obstructive Pulmonary Disease (COPD). This interactive lecture will provide an overview of the findings from this study as well as current literature associated with the topic. An advanced discussion will challenge those providers in post-acute settings to evaluate opportunities to break the cycle of disease and improve quality-of-life for our at-risk population through education and empowerment.Respiratory Management in Neuromuscular Weakness: Review of the Grading of Recommendations for Assessment, Development, and Evaluations
Clinical experts comprised a multi-professional panel to conduct a systematic review to address patients with neuromuscular diseases (NMD). A review of evidenced-based grading of recommendations and management of patients with NMD is discussed. It is part of an NMD series but can be viewed as a stand-alone learning experience.Neuromuscular Disease Review/ Management, in partnership with Midwestern State University
This course reviews neuromuscular diseases and associated treatment strategies within the scope of Respiratory Therapy. In addition, this course also discusses the importance of an interdisciplinary approach to caring for neuromuscular patients.